Cited by 1,296HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and Treatment

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Open access

Marrazzo, Jeanne M., Ramjee, Gita, Richardson, Barbra A., Gomez, Kailazarid, Mgodi, Nyaradzo, Nair, Gonasagrie, Palanee, Thesla, Nakabiito, Clemensia, van der Straten, Ariane, Noguchi, Lisa, Hendrix, Craig W., Dai, James Y., Ganesh, Shayhana, Mkhize, Baningi, Taljaard, Marthinette, Parikh, Urvi M., Piper, Jeanna, Mâsse, Benoît, Grossman, Cynthia, Rooney, James, Schwartz, Jill L., Watts, Heather, Marzinke, Mark A., Hillier, Sharon L., McGowan, Ian M., Chirenje, Z. Mike·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1402269PMC PMC4341965

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe. HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly. RESULTS: Of 12,320 women who were screened, 5029 were enrolled in the study. The rate of retention in the study was 91% during 5509 person-years of follow-up. A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years. In the modified intention-to-treat analysis, the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21). In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively. Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous. Detection of TFV in plasma was negatively associated with characteristics predictive of HIV-1 acquisition. Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P=0.004). We observed no significant differences in the frequencies of other adverse events. CONCLUSIONS: None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the National Institutes of Health; VOICE ClinicalTrials.gov number, NCT00705679.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1402269

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citation
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials
Prentice, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,444
High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa
Tanser, F. C., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M. (2013) · Science · doi:10.1126/science.1228160 · Cited by 797
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation
Liu, T. F., & Shafer, R. W. (2006) · Clinical Infectious Diseases · doi:10.1086/503914 · Cited by 661
Complex Surveys: A Guide to Analysis Using R
Lumley, T. (2010) · doi:10.1002/9780470580066 · Cited by 647

Show all 19 references

Sorted by citations

Items 801–900 of 999

Retrospective audit of a convenience cohort of individuals on HIV pre-exposure prophylaxis in Alberta, Canada
Candler, E., Khattak, M. N., Gratrix, J., Plitt, S. S., Stadnyk, M., Smyczek, P., Anderson, N., Carter, J., Sayers, S., Smith, D. J., et al. (2022) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2022-0016 · Cited by 7
Predictors of PrEP retention in at risk patients seen at a HIV primary care clinic in San Diego
Herns, S. D., Panwala, R., Pfeil, A., Sardinha, M., Rossi, V., Blumenthal, J. S., & Hill, L. A. (2023) · International Journal of STD & AIDS · doi:10.1177/09564624231179276 · Cited by 7
A qualitative study to explore daily versus on-demand oral pre-exposure prophylaxis (PrEP) in young people from South Africa, Uganda and Zimbabwe
Dietrich, J. J., Ahmed, N., Tshabalala, G., Wu, M., Mulaudzi, M., Hornschuh, S., Atujuna, M., Muhumuza, R., Ssemata, A. S., Stranix‐Chibanda, L., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287627 · Cited by 7
Broadening access to tenofovir alafenamide for the treatment and prevention of HIV-1 infection
Osuala, E. C., Naidoo, A., Dooley, K. E., Naidoo, K., & Perumal, R. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2251387 · Cited by 7
Point-of-care urine tenofovir monitoring of adherence to drive interventions for HIV treatment and prevention
Spinelli, M. A., & Gandhi, M. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2312122 · Cited by 7
A point-of-care tenofovir urine test improves accuracy of self-reported preexposure prophylaxis adherence and increases condomless sex reporting among young women
Zewdie, K., Muwonge, T. R., Ssebuliba, T., Bambia, F., Nampewo, O., Stein, G., Mugwanya, K. K., Thomas, K. K., Wyatt, C. M., Yin, M. T., et al. (2024) · AIDS · doi:10.1097/qad.0000000000003988 · Cited by 8
Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical Tenofovir
Noguchi, L., Montgomery, E., Biggio, J., Hendrix, C. W., Bogen, D. L., Hillier, S. L., Dai, J. Y., Piper, J. M., Marzinke, M. A., Dezzutti, C. S., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00645-16 · Cited by 7
What's new for antiretroviral treatment in women with HIV
Andany, N., & Walmsley, S. L. (2016) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30472-6 · Cited by 7
How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe
On behalf of the Microbicide Trials Network-003D Study Team, Musara, P., Montgomery, E., Mgodi, N. M., Woeber, K., Akello, C. A., Hartmann, M., Cheng, H., Levy, L., Katz, A. W. K., et al. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1685-x · Cited by 7
An intravaginal ring for real-time evaluation of adherence to therapy
Moss, J. A., Baum, M. M., Easley, J. T., Cox, D. M., & Smith, T. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174729 · Cited by 7
Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials
Mhlanga, F., Noguchi, L., Balkus, J. E., Kabwigu, S., Scheckter, R., Piper, J. M., Watts, H. D., O’Rourke, C., Torjesen, K., Brown, E. R., et al. (2017) · HIV Clinical Trials · doi:10.1080/15284336.2017.1411419 · Cited by 7
Pre-exposure Prophylaxis as HIV Prevention in High Risk Adolescents
Gray, M. E. (2018) · Journal of Pediatrics and Pediatric Medicine · doi:10.29245/2578-2940/2018/1.1108 · Cited by 7
Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques
Pereira, L. E., Singletary, T., Martin, A. M., Dinh, C. T., Deyounks, F., Holder, A. N., McNicholl, J. M., Buckheit, K. W., Buckheit, R. W., Ham, A. S., et al. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0538-0 · Cited by 7
Model-Based Predictions of HIV Incidence Among African Women Using HIV Risk Behaviors and Community-Level Data on Male HIV Prevalence and Viral Suppression
Moore, M., Donnell, D. J., Boily, M., Mitchell, K. M., Delany‐Moretlwe, S., Bekker, L., Mgodi, N. M., El-Sadr, W. M., Cohen, M. S., Celum, C., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002481 · Cited by 7
Enhancing oral PrEP uptake among adolescent girls and young women in Africa
Heck, C. J., & Karim, Q. A. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.25876 · Cited by 7
Sexually Transmitted Infections Among Men and Transgender Women Using HIV Pre-exposure Prophylaxis in a Large Integrated Health System—A Cohort Study
Hechter, R. C., Bruxvoort, K. J., Zhou, H. C., Towner, W. J., Contreras, R., Schumacher, C. M., Grant, D. L., & Jones, J. L. (2022) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003015 · Cited by 7
Trajectories of Oral PrEP Adherence Among Young Kenyan Women: Implications for Promoting Effective PrEP Use
Musinguzi, N., Pyra, M. N., Bukusi, E. A., Mugo, N., Baeten, J. M., Haberer, J. E., for the MPYA Study Team, Haberer, J. E., Baeten, J. M., Bukusi, E. A., et al. (2022) · AIDS and Behavior · doi:10.1007/s10461-022-03753-y · Cited by 7
Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV
Zondo, N. M., Sobia, P., Sivro, A., Ngcapu, S., Ramsuran, V., & Archary, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.940661 · Cited by 7
Examining Associations Between Mental Health, IPV Exposure, HIV Risk Behaviors, and PrEP Use in South African Women: An Analysis of Data from the Charisma Study
Triplett, N. S., Roberts, S. T., Hartmann, M., Wagner, L. D., Reddy, K., Mathebula, F., Tolley, E. E., Baeten, J. M., Palanee‐Phillips, T., & Montgomery, E. (2022) · AIDS and Behavior · doi:10.1007/s10461-022-03936-7 · Cited by 7
Adherence to daily, oral TDF/FTC PrEP during periconception among HIV-exposed South African women
Hurwitz, K. E., Isehunwa, O. O., Hendrickson, K., Jaggernath, M., Kriel, Y., Smith, P. M., Mathenjwa, M., Bennett, K. K., Psaros, C., Baeten, J. M., et al. (2023) · Frontiers in Reproductive Health · doi:10.3389/frph.2023.1263422 · Cited by 7
Evaluation of Vaginal Drug Levels and Safety of a Locally Administered Glycerol Monolaurate Cream in Rhesus Macaques
Kirtane, A. R., Rothenberger, M. K., Frieberg, A., Nephew, K. R., SCHULTZ‐DARKEN, N. J., Schmidt, T. E., Reimann, T. G., Haase, A. T., & Panyam, J. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.03.030 · Cited by 7
Evaluation of the fusion inhibitor P3 peptide as a potential microbicide to prevent HIV transmission in women
Bártolo, I., Diniz, A. R., Borrego, P., Ferreira, J. P., Bronze, M. R., Barroso, H., Pinto, R. M. A., Cardoso, C., Pinto, J. F., Diez, R. C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195744 · Cited by 7
Targeted Pregnancy and Human Immunodeficiency Virus Prevention Risk-Reduction Counseling for Young Women: Lessons Learned from Biomedical Prevention Trials
Gita Ramjee, H., Dassaye, R., Reddy, T., & Wand, H. C. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy388 · Cited by 7
Clinical testing of antiretroviral drugs as future prevention against vaginal and rectal transmission of HIV infection – a review of currently available results
Vysloužil, J., Kubová, K., Tkadlečková, V. N., & Vetchý, D. (2019) · Acta Pharmaceutica · doi:10.2478/acph-2019-0030 · Cited by 7
Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis
Srinivas, N., Cottrell, M. L., Maffuid, K., Prince, H. A., Nelson, J. A. E., White, N., Sykes, C., Dellon, E. S., Madanick, R. D., Shaheen, N. J., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01729-19 · Cited by 7
HIV research in South Africa: Advancing life
Gray, G., Doherty, T., Mohapi, L., Coetzee, J., Hopkins, K. L., Malahleha, M., Lazarus, E. M., Dietrich, J. J., Wyk, V. P., & Laher, F. (2019) · South African Medical Journal · doi:10.7196/samj.2019.v109i11b.14264 · Cited by 7
Sexual Behavior and Perceived HIV Risk Among HIV-Negative Members of Serodiscordant Couples in East Africa
the Partners Demonstration Project Team, Wanga, V., Baeten, J. M., Bukusi, E. A., Mugo, N., Asiimwe, S. B., Ngure, K., Mujugira, A., Muwonge, T. R., Odoyo, J. B., et al. (2020) · AIDS and Behavior · doi:10.1007/s10461-019-02773-5 · Cited by 7
Interference with HIV infection of the first cell is essential for viral clearance at sub-optimal levels of drug inhibition
Moyano, A., Lustig, G., Rodel, H. E., Tibor Antal, A., & Sigal, A. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007482 · Cited by 8
Prevalence and correlates of anal intercourse among female sex workers in eSwatini
Owen, B. N., Maheu‐Giroux, M., Matse, S., Mnisi, Z., Baral, S., Ketende, S. C., Baggaley, R. F., & Boily, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228849 · Cited by 7
Assessing the Scope and Predictors of Intentional Dose Non-adherence in Clinical Trials
Getz, K. A., Smith, Z., Shafner, L., & Hanina, A. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-020-00155-x · Cited by 7
Betamethasone induces potent immunosuppression and reduces HIV infection in a PBMC in vitro model
Cromarty, R. T., Sigal, A., Liebenberg, L. J. P., McKinnon, L. R., Karim, S. S. A., Passmore, J.-A. S., & Archary, D. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001424 · Cited by 7
Mapping Interests in Event-Driven and Long-Acting Pre-exposure Prophylaxis Formulations onto the HIV Risk Environment of Street-Based Female Sex Workers: A Latent Class Analysis
Rosen, J. G., Park, J. N., Schneider, K. E., White, R. H., Beckham, S. W., Glick, J. L., Footer, K. H. A., & Sherman, S. G. (2022) · AIDS and Behavior · doi:10.1007/s10461-022-03613-9 · Cited by 7
Use of a Prospective Sex Diary to Study Anal Lubricant and Enema Use Among High Risk Men Who Have Sex With Men—Implications for Human Immunodeficiency Virus Prevention
Rolle, C.-P., Bolton, M., & Kelley, C. F. (2016) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000473 · Cited by 7
Biomedical Approaches to HIV Prevention in Women
Heumann, C. L. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0618-9 · Cited by 8
Implementing a Pre-Exposure Prophylaxis Intervention for Safer Conception among HIV Serodiscordant Couples: Recommendations for Health Care Providers.
Drainoni, M., Biancarelli, D. L., Leech, A. A., Sullivan, M. M., & Bazzi, A. R. (2018) · PubMed · Cited by 7
Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies
Jacot, T. A., Clark, M. R., Adedipe, O. E., Godbout, S., Peele, A. G., Ju, S., Schwartz, J. L., Thurman, A. R., & Doncel, G. F. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0213-6 · Cited by 7
In Vivo Modulation of Cervicovaginal Drug Transporters and Tissue Distribution by Film-Released Tenofovir and Darunavir for Topical Prevention of HIV-1
Hijazi, K., Iannelli, F., Cuppone, A. M., Desjardins, D., Caldwell, A., Dereuddre‐Bosquet, N., Scala, C., Smith, K. A., Mukhopadya, I., Frank, B., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01121 · Cited by 7
Beyond the Pap Smear: Gender-responsive HIV Care for Women.
Meyer, J. P., Womack, J. A., & Gibson, B. A. (2016) · PubMed Central · Cited by 7
Preexposure Prophylaxis for HIV Infection
Siemieniuk, R. A. C., & Bogoch, I. I. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1502749 · Cited by 7
Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study
Mugwanya, K. K., Saina, M., Mugo, N., MaWhinney, S., Morrow, M., Schaafsma, T. T., Donnell, D. J., Glidden, D. V., Ngure, K., Brown, C., et al. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004732 · Cited by 6
Knowledge domain and emerging trends in HIV pre-exposure prophylaxis: A visualization analysis via CiteSpace
Chen, X., & Lai, Y. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1099132 · Cited by 6
Addressing the Need for a Preexposure Prophylaxis Monitoring and Evaluation Implementation Guide: Experience From Zambia
Lavoie, M.-C. C., Blanco, N., Mwango, L. K., Nichols, B. E., Whittington, A., Lindsay, B. R., Olufunso, A., Mujansi, M., Tembo, K., Hachaambwa, L., et al. (2023) · Global Health Science and Practice · doi:10.9745/ghsp-d-22-00396 · Cited by 7
“It’s already in your body and it’s preventing”: a qualitative study of African female adolescent’s acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa
Fynn, L., Gill, K., Wallace, M., Atujuna, M., Duyver, M., Ngcobo, P., Spiegel, H. M. L., Rinehart, A. R., Hosek, S., & Bekker, L. (2023) · BMC Public Health · doi:10.1186/s12889-023-16955-3 · Cited by 6
Development and verification of mechanistic vaginal absorption and metabolism model to predict systemic exposure after vaginal ring and gel application
Thakur, K., Telaprolu, K. C., Paterson, D., Salem, F., Arora, S., & Polak, S. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16029 · Cited by 6
The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection
Özdener-Poyraz, A. E., Park, T. E., Kalabalik, J., & Gupta, R. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1309292 · Cited by 6
Knowledge, Attitude and Practice of Healthcare Workers Towards Availability of Antiretroviral Pre-Exposure Prohylaxis in Nigeria
Afe, A. J., Adetula, A., Peter, O., Ebenezer, O., & Olonisakin, O. (2018) · Journal of Clinical Research in HIV AIDS and Prevention · doi:10.14302/issn.2324-7339.jcrhap-18-2333 · Cited by 6
The Impact of Male Partner Circumcision on Women's Health Outcomes
Moodley, J., Naidoo, S., Kelly, C., Reddy, T., & Gita Ramjee, H. (2020) · AIDS Education and Prevention · doi:10.1521/aeap.2020.32.4.356 · Cited by 6
A Mechanistic In Vivo/Ex Vivo Pharmacokinetic‐Pharmacodynamic Model of Tenofovir for HIV Prevention
Jayachandran, P., Garcia‐Cremades, M., Vučićević, K. M., Bumpus, N. N., Anton, P. A., Hendrix, C. W., & Savić, R. M. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12583 · Cited by 6
Integrating Phylogenetic Biomarker Data and Qualitative Approaches: An Example of HIV Transmission Clusters as a Sampling Frame for Semistructured Interviews and Implications for the COVID-19 Era
Hughes, S. D., Woods, W. J., O’Keefe, K. J., Delgado, V., Pipkin, S. S., Scheer, S., & Truong, H. M. (2021) · Journal of Mixed Methods Research · doi:10.1177/15586898211012786 · Cited by 6
Lobostemon trigonus (Thunb.) H. Buek, a medicinal plant from South Africa as a potential natural microbicide against HIV-1
Chawuke, P., den Berg, N. V., Fouché, G., Maharaj, V. J., Shoko, T., van der Westhuizen, C. J., Invernizzi, L., & Alexandre, K. B. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114222 · Cited by 6
Stigma and Confidentiality Indiscretions: Intersecting Obstacles to the Delivery of Pre-Exposure Prophylaxis to Adolescent Girls and Young Women in East Zimbabwe
Skovdal, M., Mandizvidza, P., Maswera, R., Moyo, M., Nyamukapa, C. A., Thomas, R., & Gregson, S. (2021) · Social aspects of HIV · doi:10.1007/978-3-030-69819-5_17 · Cited by 6
Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP
Morris, S., Cottrell, M. L., Rawlings, S. A., Peterson, S. N., Karris, M., Pacheco, D., Chaillon, A., Kay, A., Chow, K., Anderson, P. L., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002884 · Cited by 6
The ATEAM study: Advances in technology to enhance PrEP adherence monitoring ( ATEAM ) among young men who have sex with men
Brothers, J., Hosek, S., Keckler, K., Anderson, P. L., Xiong, D., Liu, H., & Huhn, G. D. (2022) · Clinical and Translational Science · doi:10.1111/cts.13414 · Cited by 7
Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study
Beauchamp, G. G., Hosek, S., Donnell, D. J., Chan, K. C. G., Flaherty, B. P., Anderson, P. L., Dye, B. J., Mgodi, N. M., Bekker, L., Delany‐Moretlwe, S., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281728 · Cited by 6
Sustained Delivery of the Antiviral Protein Griffithsin and Its Adhesion to a Biological Surface by a Silk Fibroin Scaffold
Guan, W., Zhang, N., Bains, A., Martinez, A., & LiWang, P. J. (2023) · Materials · doi:10.3390/ma16165547 · Cited by 6
Trajectories of Pre-exposure Prophylaxis Adherence Among Commercially Insured Individuals
Unigwe, I. F., Goodin, A. J., Lo‐Ciganic, W., Cook, R. L., & Park, H. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad756 · Cited by 6
PrEP: A Review for Mental Health Professionals
Pereira, L. F., Goschin, S., & Ashley, K. B. (2016) · Journal of Gay & Lesbian Mental Health · doi:10.1080/19359705.2015.1106221 · Cited by 6
Getting the balance right: Scaling-up treatment and prevention
Hoos, D., El-Sadr, W. M., & Dehne, K.-L. (2016) · Global Public Health · doi:10.1080/17441692.2016.1171887 · Cited by 6
Antiretroviral Drug Activity in Macaques Infected during Pre-Exposure Prophylaxis Has a Transient Effect on Cell-Associated SHIV DNA Reservoirs
Cong, M., Pau, C., Heneine, W., & Garcia-Lerma, J. G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164821 · Cited by 6
The Price of Prevention: Cost Effectiveness of Biomedical HIV Prevention Strategies in South Africa.
Moodley, N., Gray, G., & Bertram, M. (2016) · PubMed · Cited by 6
Optimizing adherence in HIV prevention product trials: Development and psychometric evaluation of simple tools for screening and adherence counseling
Tolley, E. E., Guthrie, K. M., Zissette, S., Fava, J. L., Gill, K., Louw, C. E., Kotze, P. L., Reddy, K., & MacQueen, K. M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195499 · Cited by 6
Reciprocal Modulation of Antiretroviral Drug and Steroid Receptor Function In Vitro
Dlamini, S., Kuipa, M., Enfield, K., Skosana, S. B., Woodland, J. G., Moliki, J. M., Bick, A. J., van der Spuy, Z. M., Maritz, M. F., Avenant, C., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01890-19 · Cited by 6
Women design their own vaginal microbicide trial: Suggestions on how to improve adherence from former participants of HIV prevention trials
Miller, L., Morar, N. S., Kapiga, S., Gita Ramjee, H., & Hayes, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244652 · Cited by 6
Quantifying geographical diversity in sexually transmitted infections using population attributable risk: results from HIV prevention trials in South Africa
Wand, H. C., Gita Ramjee, H., & Reddy, T. (2021) · International Journal of STD & AIDS · doi:10.1177/0956462420968998 · Cited by 6
The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence
Stoner, M. C. D., Brown, E. R., Palanee‐Phillips, T., Mansoor, L. E., Tembo, T., Nair, G., Akello, C. A., Seyama, L., Jeenarain, N., Naidoo, L., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03286-w · Cited by 6
Uptake of Human Papillomavirus Vaccination by HIV Status and HIV Pre-exposure Prophylaxis (PrEP) Care Engagement Among Young Sexual Minority Men 17–24 Years Old in the USA
Pleuhs, B., Walsh, J. L., Quinn, K. G., Petroll, A. E., Nyitray, A. G., & John, S. A. (2022) · Sexuality Research and Social Policy · doi:10.1007/s13178-022-00740-9 · Cited by 8
Estimating effectiveness in HIV prevention trials with a Bayesian hierarchical compound Poisson frailty model
Coley, R. Y., & Brown, E. R. (2016) · Statistics in Medicine · doi:10.1002/sim.6884 · Cited by 6
HIV pre-exposure prophylaxis (PrEP): effective but controversial
Kelen, M., & Cresswell, F. V. (2017) · Trends in Urology & Men s Health · doi:10.1002/tre.558 · Cited by 6
MODERN PREVENTION STRATEGIES OF HIV INFECTION (REVIEW OF LITERATURE)
Тахировна, А. С., & Khasanova, G. R. (1993) · Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук · doi:10.29413/abs.2018-3.1.4 · Cited by 6
Tenofovir Activating Kinases May Impact the Outcome of HIV Treatment and Prevention
Topalis, D., Snoeck, R., & Andreï, G. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.07.042 · Cited by 6
Trial of an mHealth intervention to improve HIV prophylaxis for female sex workers, United Republic of Tanzania
Mbotwa, C. H., Kazaura, M. R., Moen, K., Sudfeld, C. R., Metta, E. O., Leshabari, M. T., Bakari, M., & Mmbaga, E. J. (2024) · Bulletin of the World Health Organization · doi:10.2471/blt.24.291516 · Cited by 5
NextGen HIV prevention: new possibilities and questions
Mayer, K. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00655-3 · Cited by 5
Methods and Approaches to HIV Prevention
Balthazar, M. S. (2016) · Journal of the Association of Nurses in AIDS Care · doi:10.1016/j.jana.2016.09.005 · Cited by 5
Translational Models to Predict Target Concentrations for Pre-Exposure Prophylaxis in Women
Lantz, A. M., & Nicol, M. R. (2022) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2022.0057 · Cited by 5
Integrating Enhanced HIV Pre-exposure Prophylaxis Into a Sexually Transmitted Infection Clinic in Lilongwe: Protocol for a Prospective Cohort Study
Rutstein, S. E., Matoga, M., Chen, J. S., Mathiya, E., Ndalama, B., Nyirenda, N., Bonongwe, N., Chithambo, S., Chagomerana, M., Tegha, G., et al. (2022) · JMIR Research Protocols · doi:10.2196/37395 · Cited by 5
Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe
Friedland, B., Mgodi, N. M., Palanee‐Phillips, T., Mathur, S., Plagianos, M. G., Bruce, I. V., Lansiaux, M., Murombedzi, C., Musara, P., Dandadzi, A., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-075381 · Cited by 5
Intravaginal practices among HIV‐negative female sex workers along the US–Mexico border and their implications for emerging HIV prevention interventions
Seidman, D. L., Rusch, M., Abramovitz, D. A., Stockman, J. K., Martı́nez, G., Rangel, G., Vera, A., Ulibarri, M. D., & Strathdee, S. A. (2016) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2015.09.025 · Cited by 5
Is sub-Saharan Africa ready for pre-exposure prophylaxis?
Bernier, A., Gapiya, J., Sylla, A., Anoma, C., Somda, M., Dah, E. T. T., Flores-Aranda, J., & Himmich, H. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)00042-4 · Cited by 5
Regulatory Perspectives for Streamlining HIV Prevention Trials
Murray, J. S. (2019) · Statistical Communications in Infectious Diseases · doi:10.1515/scid-2019-0002 · Cited by 5
Validation and implementation of an ultrasensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay for dapivirine quantitation in breast milk
Manohar, M., & Marzinke, M. A. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.12.005 · Cited by 5
Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities
Janes, H., Zhu, Y., & Brown, E. R. (2020) · Statistics in Biosciences · doi:10.1007/s12561-020-09292-1 · Cited by 5
The use of PSA as a biomarker of recent semen exposure in female reproductive health studies
Mngomezulu, K., Mzobe, G. F., Mtshali, A., Baxter, C., & Ngcapu, S. (2021) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2021.103381 · Cited by 5
Evidence for use of a healthy relationships assessment tool in the CHARISMA pilot study
Tolley, E. E., Martínez, A., Zissette, S., Palanee‐Phillips, T., Mathebula, F., Tenza, S., Hartmann, M., & Montgomery, E. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261526 · Cited by 5
Dynamics of Pre-Exposure (PrEP) Eligibility Because of Waxing and Waning of HIV Risk in Rakai, Uganda
Ssempijja, V., Ssekubugu, R., Kigozi, G., Nakigozi, G. F., Kagaayi, J., Ekström, A. M., Nalugoda, F. K., Nantume, B. S., Batte, J., Kigozi, G. N., et al. (2023) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003182 · Cited by 5
Steady-state pharmacokinetics of plasma tenofovir alafenamide (TAF), tenofovir (TFV) and emtricitabine (FTC), and intracellular TFV-diphosphate and FTC-triphosphate in HIV-1 infected old Japanese patients treated with bictegravir/FTC/TAF
Tran, T. H., Tsuchiya, K., Kawashima, A., Watanabe, K., Hayashi, Y., Ryu, S., Hamada, A., Gatanaga, H., & Oka, S. (2023) · Global Health & Medicine · doi:10.35772/ghm.2023.01060 · Cited by 5
When the science fails and the ethics works: ‘Fail-safe’ ethics in the FEM-PrEP study
Kingori, P. (2015) · Anthropology and Medicine · doi:10.1080/13648470.2015.1081378 · Cited by 5
Multipurpose Prevention Approaches with Antiretroviral-Based Formulations
Jean‐Pierre, N., Barnable, P., Kizima, L., Rodríguez, A., Seidor, S., Cooney, M. L., Clark, M. R., Doncel, G. F., Robbiani, M., Zydowsky, T. M., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02468-15 · Cited by 6
Statistical issues in trials of preexposure prophylaxis
Dunn, D. T., & Glidden, D. V. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000218 · Cited by 5
Identifying Factors Associated with Low-Adherence and Subsequent HIV Seroconversions Among South African Women Enrolled in a Biomedical Intervention Trial
Wand, H. C., & Gita Ramjee, H. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1471-1 · Cited by 5
Non-Antiretroviral Microbicides for HIV Prevention.
Scott, Y., & Dezzutti, C. S. (2016) · PubMed · Cited by 5
A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near‐term pregnancy
Beigi, R. H., Noguchi, L., Montgomery, E., Biggio, J., Hendrix, C. W., Marzinke, M. A., Dai, J. Y., Pan, J., Ayudhya, R. P. K. N., Schwartz, J. L., et al. (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.1.20990 · Cited by 5
Intravaginal practices among young HIV-infected women in Lusaka, Zambia
Chisembele, M., Rodriguez, V. J., Brown, M. R., Jones, D. L., & Alcaide, M. L. (2017) · International Journal of STD & AIDS · doi:10.1177/0956462417721438 · Cited by 5
Cost-Effectiveness of Interventions to Prevent HIV Acquisition
Garnett, G. P., Krishnaratne, S., Harris, K. L., Hallett, T. B., Santos, M. A., Enstone, J. E., Hensen, B., Dallabetta, G., Revill, P. A., Gregson, S., et al. (2017) · doi:10.1596/978-1-4648-0524-0/ch7 · Cited by 5
Recruitment of Female Sex Workers in HIV Prevention Trials: Can Efficacy Endpoints Be Reached More Efficiently?
Wood, D. T., Lancaster, K. E., Boily, M., Powers, K. A., Donnell, D. J., Cohen, M. S., & Dimitrov, D. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001603 · Cited by 5
Estimating Human Immunodeficiency Virus (HIV) Prevention Effects in Low-incidence Settings
Rudolph, J. E., Cole, S. R., Eron, J. J., Kashuba, A. D. M., & Adimora, A. A. (2019) · Epidemiology · doi:10.1097/ede.0000000000000966 · Cited by 5
The paradox of HIV prevention: did biomedical prevention trials show how effective behavioral prevention can be?
O’Reilly, K., Fonner, V. A., Kennedy, C. E., Yeh, P. T., & Sweat, M. D. (2020) · AIDS · doi:10.1097/qad.0000000000002682 · Cited by 5
Sharing Objective Measures of Adherence to a Vaginal Microbicide Promotes Candor About Actual Use and Bolsters Motivation to Prevent HIV
Kutner, B. A., Giguere, R., Lentz, C. L., Kajura-Manyindo, C., Dolezal, C. L., Butheliezi, S., Gwande, M., Nampiira, S., Ndlovu, T., Mvinjelwa, P., et al. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-03026-6 · Cited by 5
Pre‐Exposure Prophylaxis for HIV Infection and the Role of the Women's Health Care Provider in HIV Prevention
Ruppe, L. B., Spencer, L. A., & Kriebs, J. M. (2021) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13231 · Cited by 5
Monitoring Antihypertensive Medication Adherence by Liquid Chromatography–Tandem Mass Spectrometry: Method Establishment and Clinical Application
Wang, Y., Wang, J. W., Wang, Y., Yang, B., Du, A., Kong, Z., Chen, M., & Wang, J. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001105 · Cited by 5
In-Situ Implant Formulation of Laurate and Myristate Prodrugs of Dolutegravir for Ultra-Long Delivery
Khuroo, T., Mohamed, E. M., Dharani, S., Immadi, S. S., Nutan, M. T. H., Lu, D., Ali, H. I., Khan, M. A., & Rahman, Z. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.03.007 · Cited by 5

Authors: Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., Hendrix, C. W., Dai, J. Y., Ganesh, S., Mkhize, B., Taljaard, M., Parikh, U. M., Piper, J., Mâsse, B., Grossman, C., Rooney, J., Schwartz, J. L., Watts, H., Marzinke, M. A., Hillier, S. L., McGowan, I. M., & Chirenje, Z. M.
Affiliations: University of California, San Francisco (US)
Harborview Medical Center (US)
Family Health International 360 (US)
University of Zimbabwe (ZW)
Centre for the AIDS Programme of Research in South Africa (ZA)
University of Pittsburgh (US)
Johns Hopkins University (US)
South African Medical Research Council (ZA)
National Institutes of Health (US)
Eastern Virginia Medical School (US)
ORCID: Marrazzo, Jeanne M.
Richardson, Barbra A.
Gomez, Kailazarid
Mgodi, Nyaradzo
Nair, Gonasagrie
Nakabiito, Clemensia
Noguchi, Lisa
Hendrix, Craig W.
Dai, James Y.
Parikh, Urvi M.
Piper, Jeanna
Mâsse, Benoît
Rooney, James
Watts, Heather
Marzinke, Mark A.
Hillier, Sharon L.
McGowan, Ian M.
Chirenje, Z. Mike
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-02-05
Volume: 372
Issue: 6
Pages: 509-518
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1402269
PMC: PMC4341965
OpenAlex: W2044369525
Cited by: 1,296
References: 19
Citations by year: 2026: 32 · 2025: 54 · 2024: 59 · 2023: 78 · 2022: 93 · 2021: 143 · 2020: 125 · 2019: 139 · 2018: 122 · 2017: 140 · 2016: 175 · 2015: 131
FWCI: 147.62
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
Funders: National Institute of Allergy and Infectious Diseases (U01AI068633, UM1AI068615, UM1AI069422, UM1AI106707, UM1AI069436, P30AI094189, UM1AI069530, UM1AI069463, UM1AI069469)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: tenofovir disoproxil fumarate, tenofovir/emtricitabine, HIV pre-exposure prophylaxis, HIV-1 prevention, women, women of reproductive age, antiretroviral resistance, tenofovir resistance, drug safety, adverse events, creatinine elevation
MeSH terms: Emtricitabine, Tenofovir, Adenine, Administration, Intravaginal, Administration, Oral, Adolescent, Adult, Deoxycytidine, Drug Therapy, Combination, Female, HIV Seropositivity, Humans, Middle Aged, Surveys and Questionnaires, HIV-1, HIV Infections, Africa South of the Sahara, Drug Resistance, Viral, Anti-Retroviral Agents, Medication Adherence, Young Adult, Organophosphonates, Pre-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks